Ftse Mib
33.843,83
1,08%
DAX
20.016,75
0,55%
S&P 500
6.040,17
-0,12%
NASDAQ
19.411,56
0,04%
Bitcoin
95.415,28
-0,46%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aptose Biosciences Inc (APTO) Aptose Biosciences Inc (APTO) Notizie

APTO

Aptose Biosciences (APTO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:APTO
DataOraFonteTitoloSimboloCompagnia
03/12/202413:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
03/12/202413:30GlobeNewswire Inc.Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine TrialsNASDAQ:APTOAptose Biosciences Inc
27/11/202400:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APTOAptose Biosciences Inc
25/11/202422:15GlobeNewswire Inc.Aptose Biosciences Inc. Announces Closing of $8 Million Public OfferingNASDAQ:APTOAptose Biosciences Inc
25/11/202412:05Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:APTOAptose Biosciences Inc
22/11/202414:00GlobeNewswire Inc.Aptose Biosciences Inc. Announces Pricing of $8 Million Public OfferingNASDAQ:APTOAptose Biosciences Inc
22/11/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:APTOAptose Biosciences Inc
20/11/202413:30GlobeNewswire Inc.Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet TherapyNASDAQ:APTOAptose Biosciences Inc
14/11/202421:22Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:APTOAptose Biosciences Inc
08/11/202422:01GlobeNewswire Inc.Aptose Reports Results for the Third Quarter 2024NASDAQ:APTOAptose Biosciences Inc
31/10/202411:39Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:APTOAptose Biosciences Inc
05/09/202422:15GlobeNewswire Inc.Aptose Announces Results from Special Meeting of ShareholdersNASDAQ:APTOAptose Biosciences Inc
30/08/202422:30GlobeNewswire Inc.Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop TuspetinibNASDAQ:APTOAptose Biosciences Inc
15/08/202422:30GlobeNewswire Inc.Aptose Announces Adjournment of its Special Meeting of ShareholdersNASDAQ:APTOAptose Biosciences Inc
08/08/202423:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APTOAptose Biosciences Inc
08/08/202423:06GlobeNewswire Inc.Aptose Reports Results for the Second Quarter 2024NASDAQ:APTOAptose Biosciences Inc
19/07/202423:00GlobeNewswire Inc.Aptose Announces Receipt of Deficiency Notice from NasdaqNASDAQ:APTOAptose Biosciences Inc
17/07/202417:43Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:APTOAptose Biosciences Inc
03/06/202412:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APTOAptose Biosciences Inc
14/02/202422:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:APTOAptose Biosciences Inc
26/01/202403:44Edgar (US Regulatory)Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]NASDAQ:APTOAptose Biosciences Inc
21/09/202323:10Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:APTOAptose Biosciences Inc
06/07/202322:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:APTOAptose Biosciences Inc
26/06/202322:11Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:APTOAptose Biosciences Inc
20/06/202312:01Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:APTOAptose Biosciences Inc
19/04/202312:02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:APTOAptose Biosciences Inc
03/04/202322:23Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:APTOAptose Biosciences Inc
24/03/202311:01Edgar (US Regulatory)Annual Report (10-k)NASDAQ:APTOAptose Biosciences Inc
14/02/202323:19Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:APTOAptose Biosciences Inc
17/01/202312:08Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:APTOAptose Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:APTO

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
UCG
Unicredit
BIT
ENEL
Enel
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
SPM
Saipem
BIT
MONC
Moncler
BIT
BPE
Bper Banca
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BAMI
Banco BPM
BIT
NEXI
Nexi S.p.A
BIT
RACE
Ferrari NV
BIT
TEN
Tenaris
BIT
TRN
Terna Trasmissione Elett...
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network